CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,912 target
Drug / intervention
abciximab intracoronary +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00712101
NCT00712101Phase 3Completed
CompareCT.gov

Prospective Randomized Controlled Clinical Study to Compare Abciximab-bolus i.v. Versus i.c. in Primary PCI in Patients With Acute ST-elevation Myocardial Infarction

University of Leipzig·interventional·Posted Jul 9, 2008·Updated Apr 20, 2011

In Brief

A Phase 3 clinical trial evaluating abciximab intracoronary and abciximab intravenously for ST-elevation Myocardial Infarction. Completed, enrolled 1,912 participants across 11 sites.

Detailed Summary

The purpose of this study is to examine whether intracoronary abciximab bolus application with subsequent 12 hour intravenous infusion in addition to primary percutaneous coronary intervention is beneficial for patients with STEMI in comparison to standard i.v. bolus application with respect to 90-day mortality, reinfarction and new congestive heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsST-elevation Myocardial Infarction
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 9, 2008
Enrollment StartJul 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.0 years ago

Interventions

abciximab intracoronarydrug

administer abciximab bolus intracoronary during primary percutaneous coronary intervention

abciximab intravenouslydrug

administer abciximab bolus intravenously during primary percutaneous coronary intervention